Novo Nordisk A/S $NVO Shares Acquired by Baird Financial Group Inc.

Baird Financial Group Inc. grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 42.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,476,673 shares of the company’s stock after purchasing an additional 441,034 shares during the quarter. Baird Financial Group Inc.’s holdings in Novo Nordisk A/S were worth $101,920,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Revolve Wealth Partners LLC grew its holdings in Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Novo Nordisk A/S in the 1st quarter valued at about $41,000. Cary Street Partners Financial LLC grew its stake in shares of Novo Nordisk A/S by 9.0% during the first quarter. Cary Street Partners Financial LLC now owns 30,579 shares of the company’s stock valued at $2,123,000 after acquiring an additional 2,527 shares in the last quarter. Encompass More Asset Management increased its position in shares of Novo Nordisk A/S by 22.6% during the first quarter. Encompass More Asset Management now owns 4,164 shares of the company’s stock worth $289,000 after acquiring an additional 767 shares during the last quarter. Finally, Cary Street Partners Investment Advisory LLC lifted its stake in shares of Novo Nordisk A/S by 105.4% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 2,126 shares of the company’s stock worth $148,000 after acquiring an additional 1,091 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on NVO shares. Morgan Stanley restated an “underweight” rating and set a $42.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 16th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Dbs Bank upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, August 22nd. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Novo Nordisk A/S in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $56.00.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $47.51 on Thursday. The firm has a fifty day moving average of $52.10 and a 200-day moving average of $59.33. The company has a market cap of $212.11 billion, a price-to-earnings ratio of 13.81 and a beta of 0.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The business had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.